Alefacept response lingers in psoriatic patients

July 1, 2002

New Orleans - Psoriatic patients achieving >75 percentreduction in PASI score with one course of alefacept (Amevive) followedby treatment-free follow-up maintained >50 percent reduction for at leasteight months.

Related Content:

Pediatric Dermatology